Case report: Management of pediatric gigantism caused by the TADopathy, X-linked acrogigantism.

GPR101 gigantism pituitary tumor somatostatin analog topologically associating domain (TAD)

Journal

Frontiers in endocrinology
ISSN: 1664-2392
Titre abrégé: Front Endocrinol (Lausanne)
Pays: Switzerland
ID NLM: 101555782

Informations de publication

Date de publication:
2024
Historique:
received: 27 11 2023
accepted: 02 02 2024
medline: 14 3 2024
pubmed: 14 3 2024
entrez: 14 3 2024
Statut: epublish

Résumé

X-linked acrogigantism (X-LAG) is a rare form of pituitary gigantism that is associated with growth hormone (GH) and prolactin-secreting pituitary adenomas/pituitary neuroendocrine tumors (PitNETs) that develop in infancy. It is caused by a duplication on chromosome Xq26.3 that leads to the misexpression of the gene

Identifiants

DOI: 10.3389/fendo.2024.1345363 PMID: 38481440 PMC: PMC10932951
pubmed: 38481440
doi: 10.3389/fendo.2024.1345363
pmc: PMC10932951
doi:

Types de publication

Case Reports

Langues

eng

Sous-ensembles de citation

IM

Pagination

1345363

Informations de copyright

Copyright © 2024 Caruso, Mazzatenta, Asioli, Costanza, Trivellin, Franke, Abboud, Hanson, Raverot, Pétrossians, Beckers, Cappa and Daly.

Déclaration de conflit d'intérêts

AD, GT, and AB hold a patent on GPR101 and its function US Patent No. 10,350,273, Treatment of Hormonal Disorders of Growth. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Auteurs

Manuela Caruso (M)

Department of Pediatrics, Azienda Policlinico Università di Catania, Catania, Italy.

Diego Mazzatenta (D)

Department of Biomedical and Neuromotor Sciences (DIBINEM), Alma Mater Studiorum, University of Bologna, Bologna, Italy.
Istituto di Ricovero e Cura a Carattere Scientifico Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy.

Sofia Asioli (S)

Department of Biomedical and Neuromotor Sciences (DIBINEM), Alma Mater Studiorum, University of Bologna, Bologna, Italy.
Istituto di Ricovero e Cura a Carattere Scientifico Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy.

Giuseppe Costanza (G)

Department of Pediatrics, Azienda Policlinico Università di Catania, Catania, Italy.

Giampaolo Trivellin (G)

Department of Biomedical Sciences, Humanitas University, Milan, Italy.
Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Humanitas Research Hospital, Milan, Italy.

Martin Franke (M)

Andalusian Center for Developmental Biology (CABD), Junta de Andalucía- Universidad Pablo de Olavide (UPO) - Consejo Superior de Investigaciones Cientificas (CSIC), Sevilla, Spain.

Dayana Abboud (D)

Center for Interdisciplinary Research on Medicines (CIRM) - Laboratory of Medicinal Chemistry, and Laboratory of Molecular Pharmacology, GIGA-Molecular Biology of Diseases, University of Liège, Liège, Belgium.

Julien Hanson (J)

Center for Interdisciplinary Research on Medicines (CIRM) - Laboratory of Medicinal Chemistry, and Laboratory of Molecular Pharmacology, GIGA-Molecular Biology of Diseases, University of Liège, Liège, Belgium.

Véronique Raverot (V)

Laboratoire d'hormonologie Centre de Biologie et Pathologie Est (CBPE)-Groupement Hospitalier Est, Hospices civils de Lyon, Bron, France.

Patrick Pétrossians (P)

Department of Endocrinology, Centre Hospitalier Universitaire de Liège, University of Liège, Liège, Belgium.

Albert Beckers (A)

Department of Endocrinology, Centre Hospitalier Universitaire de Liège, University of Liège, Liège, Belgium.

Marco Cappa (M)

Research Unit, Innovative Therapies for Endocrinopathies, Scientific Directorate, Bambino Gesù Children's Hospital, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Rome, Italy.

Adrian F Daly (AF)

Department of Endocrinology, Centre Hospitalier Universitaire de Liège, University of Liège, Liège, Belgium.

Classifications MeSH